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Maspin, a mammary serine protease inhibitor, was originally reported to be a tumor suppressor gene in breast and
prostate cancers. The expression pattern of the maspin gene differs among cancer types and normal tissue
however, and its signiﬁcance as a tumor suppressor has been questioned. In this study, maspin expression and/or
allele-speciﬁc methylation status were investigated in ﬁve melanoma cell lines and a normal human epidermal
melanocyte (NHEM) cell line, and 80 surgically resected tumors (40 melanomas and 40 melanocytic nevi). One
(HMV-I) of ﬁve melanoma cell lines overexpressed maspin protein whereas the remaining four melanoma cell lines
and NHEM did not. The 19 CpG sites of the maspin promoter region were extensively hypomethylated in HMV-I, a
maspin-positive cell line, and those of the remaining four melanoma and NHEM cell lines were hypermethylated.
Furthermore, maspin-negative cell lines exhibited activation after treatment with 5-aza-20-deoxycytidine, a DNA
demethylating agent. Immunoreactivity for maspin was negative in normal skin melanocytes and 40 melanocytic
nevi, but ﬁve (12.5%) of 40 melanomas were positive. The methylation status judged by the methylation-speciﬁc
PCR method was inversely correlated with maspin protein expression in vitro and in vivo. These results suggest
that maspin expression in normal skin melanocytes and melanocytic nevi may be repressed in a cell-type-speciﬁc
manner, whereas maspin is expressed aberrantly in a subset of melanoma cells by epigenetic modiﬁcation. Further
investigations are required to determine the signiﬁcance of aberrant maspin expression.
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Maspin is a member of the serine protease inhibitor family,
related to the serpin family (Zou et al, 1994). The maspin
gene was originally identified in normal mammary epithelial
cells (Zou et al, 1994). A maspin-transfected mammary
cancer cell line was found to have reduced capacity for
tumorigenesis and metastasis in nude mice (Zou et al,
1994). Maspin has been shown to have tumor-suppressive
activity attributed to inhibition of breast cancer cell motility,
invasion, and metastasis (Sheng et al, 1994, 1996, 1998;
McGowen et al, 2000; Biliran and Sheng, 2001; Shi et al,
2001). Loss of maspin protein expression has been
observed frequently and is associated with poor prognosis
in breast, prostatic, and oral cancer (Xia et al, 2000; Maass
et al, 2001a,b; Machtens et al, 2001; Umekita et al, 2002).
Recent studies have suggested that maspin interacts with
the p53 tumor suppressor pathway (Zou et al, 2000) and
may function as an inhibitor of angiogenesis (Zhang et al,
2000) in vitro and in vivo. These observations suggest that
maspin acts as a tumor suppressor gene.
The significance of the maspin gene as a tumor
suppressor in breast cancers has recently been questioned
(Lele et al, 2000; Reis-Filho et al, 2001, 2002a, 2003;
Umekita et al, 2002; Mohsin et al, 2003; Umekita and
Yoshida, 2003). Immunohistochemical studies have demon-
strated positive immunoreactivity only in myoepithelial cells
and not in normal breast epithelial cells. Furthermore,
variable maspin expression has been described in different
types of cancer cells. Overexpression was observed in
pancreatic (Maass et al, 2001b) and ovarian (Sood et al,
2002) cancer, whereas normal tissue was maspin-negative.
Precancerous lesions also express maspin protein, and its
upregulation is correlated with malignant behavior (Maass
et al, 2001b; Sood et al, 2002). In these tumors, maspin
seems to behave as an oncogene rather than a tumor
suppressor gene.
Recently, Futscher et al (2002) demonstrated that maspin
expression in normal cells is regulated by epigenetic
modification in a cell-type-specific manner. Maspin-positive
cells (mammary/prostatic epithelia and skin/oral keratino-
cytes) showed no methylation at the CpG islands of the
promoter region. In contrast, maspin-negative cells (skin
fibroblasts, lymphocytes, heart, liver, and bone marrow)
showed extensive methylation. For maspin-negative cells,
gene repression by epigenetic modification is necessary to
maintain homeostasis and morphological differentiation.
Epigenetic changes have been recognized as an
important underlying mechanism in the tumorigenesis of
human malignancies including skin tumors. Reis-Filho et al
(2002b) examined maspin immunoreactivity in normal
epidermis, appendages, squamous cell carcinoma (SCC),
and basal cell carcinoma (BCC). They demonstrated thatAbbreviation: NHEM, normal human epidermal melanocyte
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maspin was expressed consistently in the cytoplasm of
normal epidermis and appendages (keratinocytes of the
suprabasal, granular, and spinous layers, in terminally
differentiated sebaceous cells and the inner root sheath
cells of hair follicles). SCC expressed maspin strongly but
BCC showed variable maspin expression. An immunohis-
tochemical study using the tissue microarray technique
demonstrated that five (23%) of 22 melanoma cases
showed positive immunoreactivity for maspin but that the
immunoreactivity was not significantly correlated with p53
status (Zhang and Zhang, 2002). Maspin expression and/or
its regulation mechanism have not been systematically
examined in normal melanocytes of the skin or melanocytic
tumors. In this study, maspin expression and/or methylation
status were examined in normal skin melanocytes, surgi-
cally resected melanocytic nevi and melanomas, and
melanoma cell lines.
Results
Maspin expression and methylation status in melanoma
cell lines Expression of maspin protein was detected in
only one melanoma cell line, HMV-I, by western blotting. No
maspin expression was detected in the remaining four
melanomas (CRL1579, G361, HMV-II, and SK-MEL-28) and
NHEM (Fig 1a). When these cell lines were treated with the
demethylating agent 5-Aza-dC, three (CRL1579, G361, and
SK-MEL-28) became strongly positive for maspin expres-
sion by western blotting (Fig 1b), and one melanoma (HMV-
II) and NHEM cell line became weakly positive (Fig 1b).
Quantitative determination of maspin mRNA by RQ-PCR
showed an endogenous level or none (no PCR products
were visualized with ethidium bromide) in the maspin-
negative cell lines, but upregulated expression after treat-
ment with 5-Aza-dC (Table I and Fig 2). Furthermore, HMV-I
was also overexpressed at an extremely high level. These
results indicate that maspin expression was regulated by
epigenetic modification in the melanoma cell lines as well as
in the NHEM cell line. The methylation status of the maspin
gene promoter was therefore investigated using the bisulfite
genome sequencing method. One single-nucleotide poly-
morphism site (SNP) was present in the sequenced region
(Fig 3a). The allele-specific methylation status in a maspin-
positive cell line (HMV-I) could be determined using this
SNP (Fig 3b). The maspin promoter region of HMV-I was
extensively hypomethylated; 10 of 19 CpG sites were
completely unmethylated and nine sites were 10%–40%
methylated. Cytosine methylations occurred randomly but
were not allele-specific. In contrast, the four maspin-
negative melanoma cell lines (CRL1579, G361, SK-MEL-28,
and HMV-II) and the NHEM cell line were hypermethylated
(Fig 3b). The methylation status at the maspin promoter was
inversely correlated with the expression of both its mRNA
and protein.
Figure 1
Western blot analysis of maspin expression before (a) and after (b)
treatment with 5-Aza-dC in five melanoma cell lines and a normal
human epidermal melanocyte (NHEM). (a) Maspin protein expression
was observed in the melanoma cell line HMV-I. (b) Expression of the
maspin protein was observed in four melanoma cell lines and NHEM
after treatment with 5-Aza-dC. (c) Equal loading was confirmed by
incubation with an anti-actin antibody (C-2, Santa Cruz Biotechnology,
Santa Cruz, California).
Figure2
Results of real-time quantitative PCR (a) and agarose gel electro-
phoresis (b) for maspin mRNA in melanoma cell lines. (a)
Amplification plots of G361 (a: non-treatment control; a0: treatment
with 5-Aza-dC) and HMV-1 (b: non-treatment control; b0: treatment with
5-Aza-dC). (b) No PCR products were visualized in four maspin protein-
negative cell lines by ethidium bromide staining. These became
activated after treatment with 5-Aza-dC. SM, size marker.
Table I. Results of RQ-PCR assay for measuring
maspin mRNA
Cell lines
Copy number of maspin/104 GAPDH
Before treatment After treatment
HMV-I 436.36 1053.3
CRL1579 0.136 118.6
G361 0.6 326.1
HMV-II 0 297.8
SK-MEL-28 0.146 226.7
NHEM 0 59.3
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Immunohistochemistry Maspin expression was comple-
tely negative in normal skin melanocytes. The immunor-
eactivity for maspin in the other types of normal skin cells
was identical to that described previously (Reis-Filho et al,
2002a,b). In particular, the immunoreactivity of skin fibro-
blasts was completely negative (Fig 4), and that of skin
keratinocytes was strongly positive (Fig 4), making them
good internal controls for maspin immunohistochemistry.
For both cell types, methylation status at the promoter
region and mRNA expression have already been examined
by Futscher et al (2002). Maspin expression was observed
in five (12.5%) of the 40 surgically resected melanomas, but
not in 40 melanocytic nevi. Two melanomas in situ (Stage 0)
showed the focal and moderate immunoreactivity for
maspin (Fig 4a). Two of the three Stage I melanomas exhi-
bited weak immunoreactivity at the epidermal–dermal
junction. The remaining one showed moderate immuno-
reactivity at both the epidermal–dermal junction and
throughout the dermis (Fig 4b, c).
Subcellular localization of maspin protein was observed
in the cytoplasm, but not in the nucleus. There was no
significant correlation between the results of immunostain-
ing and clinicopathological data (Table II).
MSP Using the MSP method, we evaluated the promoter
status at the maspin gene in six melanocytic cell lines and
80 resected tumors. In the six melanocytic cell lines, our
MSP primer sets were able to correctly distinguish their
methylation status at the maspin promoter compatible with
the results of sequencing and protein expression (Fig 5). For
analyses of five maspin-positive tumors, DNAs were
extracted from microdissected materials using the LCM
technique (Fig 6). Positive signals for an unmethylated (U)
primer set were observed in only five melanomas (Fig 5b), all
of which showed positive immunoreactivity for maspin. Four
of them showed no signals for a methylated (M) primer set,
but one was positive (Fig 5b). We also tested the primer sets
in a series of 24 human malignant tumor cell lines (four
gastric cancer, ten hepatocellular carcinoma, eight colonic
cancer, and two osteosarcoma cell lines, data not shown).
Some of them (e.g., a gastric cancer cell line, MKN74)
showed demethylation allele-specifically on the haploid
allele. In the tumor, both sets for the M- and U-primers
showed a positive signal (data not shown). We had pre-
viously confirmed that demethylation of the haploid allele
produced abundant protein expression in maspin-positive
gastric cancer cell lines and normal epithelium. This type of
the tumor was judged to be unmethylated. Two hypotheses
Figure 3
(a) Diagram of the maspin gene promoter region and (b) methyla-
tion status in melanocytic cell lines. (a) The vertical lines mark the
location of CpG dinucleotide sites. The bent arrow indicates the
transcription start site. The locations of nested PCR primers (U2/D2
and U3/D3) are indicated by arrows. The SNP site (–156) is indicated by
an arrowhead. Pst I indicates the position of the restriction site. (b)
Location and methylation status of 19 CpG sites in the maspin gene
promoter. Each row of circles represents the methylation pattern
obtained from individual clones of the maspin gene promoter. Each
circle represents a CpG dinucleotide site. The solid circles indicate
methylation positivity and the clear circles indicate methylation
negativity. The number at the top indicates the position of each CpG
site relative to the major transcription start site. The allele status of each
clone at the SNP site is indicated on the right.
Figure 4
Immunohistochemistry for maspin in two melano-
mas. Colorization was achieved with a True Blue
Peroxidase Substrate Kit so that the immunoreactive
area was stained blue. (a) Weak immunoreactivity for
maspin is observed in melanoma cells of the epidermis
in comparison with strong immunoreactivity in kerati-
nocytes (Stage 0). (b) Low-power view of immunostain-
ing in a Stage I melanoma. Maspin-positive melanoma
cells are observed throughout the dermis. (c) High-
power view of melanoma cells indicated by the arrows
in (b). Positive staining is evident in the cytoplasm.
Scale bars: 100 mm.
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were developed for a melanoma exhibiting positive signals
for both M- and U-primer sets: contamination with non-
tumor cells or a difference in methylation status between the
alleles. PCR was successful for the M-primer set in 40
melanocytic nevi and 35 melanomas (Fig 5b). Methylation
status judged by MSP primer sets showed a good inverse
correlation with the results of immunohistochemical staining
(po0.01, Table III).
Discussion
This study demonstrates that aberrant expression of the
maspin gene occurs due to demethylation of its promoter
region in a subset of melanomas in vitro and in vivo.
Domann and colleagues (Domann et al, 2000; Futscher et al,
2002) showed that maspin expression is controlled by the
methylation status of its CpG island, and that maspin-non-
expressing normal cells are methylated completely at the
CpG island, resulting in transcriptional repression. These
authors concluded that CpG methylation is important in the
establishment and maintenance of cell-type-restricted gene
expression. Their report provided an influential insight into
the controversial issue of whether DNA methylation controls
tissue-specific gene expression (Costello and Vertino,
2002). From this viewpoint, maspin expression might be
repressed in a cell-type-specific manner in normal skin
melanocytes and melanocytic nevi.
Recent epigenetic studies have shown that the silencing
of tumor-related genes due to hypermethylation might play
an important role in melanoma development (Huang et al,
1997; Worm et al, 2000; Christmann et al, 2001; Soengas
et al, 2001; Feng et al, 2002; Sigalotti et al, 2002; Straume
et al, 2002). A few reports have indicated that specific gene
expression associated with promoter hypomethylation
contributes to melanoma development (De Smet et al,
1996; Serrano et al, 2001). It has been suggested that
extensive DNA hypomethylation precedes cancer-linked
DNA hypermethylation (Feinberg and Vogelstein, 1983;
Gama-Sosa et al, 1983). DNA hypomethylation in cancer
often affects more of the genome than hypermethylation,
resulting in net losses of genomic 5-methylcytosine in many
human cancers (Gama-Sosa et al, 1983). In an experimental
analysis of DNA methyltransferase-deficient mice, Jaenisch
and colleagues (Eden et al, 2003; Gaudet et al, 2003) have
recently demonstrated that DNA hypomethylation plays a
causal role in tumor formation, possibly by promoting
chromosomal instability. The role of cancer-linked DNA
hypomethylation is now drawing more attention in cancer
research (Ehrlich, 2002; Ehrlich et al, 2002). It is unclear
whether hypomethylation occurs selectively at the maspin
locus, or is a simple result of genome-wide DNA hypo-
methylation.
Table II. Correlation of maspin expression and
clinicopathological data in melanoma patients
Characteristics Total
Maspin immunoreactivity
Positive (%) Negative (%)
Tumor location
Head and neck 7 1 (14) 6 (86) NS
Trunk 6 1 (17) 5 (83)
Extremities 9 1 (11) 8 (89)
Acral 18 2 (11) 16 (89)
Typea
ALM 15 2 (13) 13 (87) NS
LMM 7 1 (14) 6 (86)
NM 10 0 (0) 10 (100)
SSM 8 2 (25) 6 (75)
Tumor thickness
p1.0 mm 13 5 (38) 8 (62) NS
1.0–2.0 mm 7 0 (0) 7 (100)
2.0–4.0 mm 6 0 (0) 6 (100)
X4.0 mm 14 0 (0) 14 (100)
Clinical stageb
0 11 2 (18) 9 (82) NS
I 5 3 (60) 2 (40)
II 13 0 (0) 13 (100)
III 6 0 (0) 6 (100)
IV 5 0 (0) 5 (100)
NS, not significant.
aALM, acral lentiginous melanoma; LMM, lentigo maligna melanoma;
NM, nodular melanoma; SSM, superficial spreading melanoma.
bClinical stage was defined according to the melanoma TNM
classification (Balch et al, 2001).
Figure5
Methylation-specific PCR analyses for maspin in melanocytic cell
lines (a) and surgically resected melanocytic tumors (b). (a) A
maspin-positive melanoma cell line, HMV-I (lane 3), shows a positive
signal only in an unmethylated primer set (U) but not in a methylated
primer set (M). Four other maspin-negative melanoma cell lines (lanes
1, 2, 4, and 5) and a normal human epidermal melanocyte cell line
(NHEM; lane 6) show a positive signal in the M-primer. Lane 7 is a
positive control for the M-primer set (HOTHC, thyroid cancer) and lane
8 is a positive control for the U-primer set (KHM-5M, thyroid cancer). (b)
PCR was successful for the U-primer set in five maspin-positive
melanomas (lanes 1–5). One of them (lane 4) is also positive for the
U-primer set. Two hypotheses can account for melanomas exhibiting
positive signals for both the M- and U-primer sets: contamination by
non-tumor cells or a difference in methylation status between the
alleles. PCR is successful only for the M-primer set in two melanocytic
nevi (lanes 8 and 9) and two maspin-negative melanomas (lanes 6 and
7). Lanes 9 and 10 are positive controls for the M-primer set (HOTHC,
thyroid cancer) and for the U-primer set (KHM-5M, thyroid cancer),
respectively.
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Up to now, the maspin gene has been considered to be
tumor suppressor gene; however, maspin seems to behave
as an oncogene rather than a tumor suppressor gene in
pancreatic (Maass et al, 2001b) and ovarian (Sood et al,
2002) cancer. Sood et al (2002) demonstrated that patients
with invasive ovarian cancer exhibiting maspin upregulation
had a poor prognosis. In addition, nuclear subcellular
localization of maspin protein was frequently observed in
ovarian tumors with low malignant potential, and invasive
tumors also expressed cytoplasmic staining (Sood et al,
2002). The authors hypothesized that the maspin expres-
sion in these tumors might be inactive. Although immunor-
eactivity of maspin-positive melanomas was observed only
in the cytoplasm, the significance of maspin protein
subcellular localization has been controversial (Reis-Filho
et al, 2002a,b). Definitive evidence for the subcellular local-
ization hypothesis will require a functional assay of maspin
activity.
The gene expression profile of gastric cancers was
recently investigated using cDNA microarray, and it was
demonstrated that expression of maspin was significantly
higher in tumors with lymph node metastasis than in those
without (Terashima et al, submitted for publication). In
melanomas, no association with any clinicopathological
parameters was detected. Further studies are needed to
clarify the functional significance of maspin overexpression
in melanomas.
Materials and Methods
Cell lines and clinical specimens Five human melanoma cell
lines (HMV-I, HMV-II, CRL1579, G361, and SK-MEL-28) and a
normal human epidermal melanocyte cell line (NHEM) were
obtained from the Cell Resource Center for Biomedical Research,
Tohoku University (Sendai, Japan), and Cascade Biologics Inc.
(Portland, Oregon), respectively. These cells were maintained
under the recommended conditions. Surgical specimens from 80
patients, consisting of 40 melanomas and 40 melanocytic nevi,
were subjected to immunohistochemistry for maspin. The char-
acteristics of the patients are summarized in Table IV. Permission
for this study was obtained from the Institutional Review Board
(Iwate Medical University School of Medicine, Morioka, Japan).
The experiments conducted in this study were done in accordance
with Helsinki Principles.
Bisulﬁte modiﬁcation and PCR ampliﬁcation The methylation
status of 19 CpG dinucleotides within the maspin gene promoter
region was examined in bisulfite-modified DNA (Zhang et al, 1997;
Domann et al, 2000). Genomic DNA was digested with Pst I and
then subjected to bisulfite modification as described previously
(Clark et al, 1994). Briefly, 1 mg of genomic DNA was denatured by
treatment with NaOH and modified with sodium bisulfite. Samples
were then purified using Wizard DNA purification resin (Promega,
Madison, Wisconsin), treated with NaOH, precipitated with
ethanol, and resuspended in water. Modified DNA was amplified
by PCR under conditions described previously (Futscher et al,
2002). The maspin gene promoter was amplified from bisulfite-
modified DNA by two rounds of PCR using nested primers specific
to the bisulfite-modified sequence of the maspin gene CpG island.
The first-round primers were: primer U2 (nt 284 to 255), 50-AAA
AGA ATG GAG ATT AGA GTA TTT TTT GTG-30; primer D2 (nt 157–
184), 50-CCT AAA ATC ACA ATT ATC CTA AAA AAT A-30 (Futscher
et al, 2002). The second-round primers were: primer U3 (nt 238
to 212) 50-GAA ATT TGT AGT GTT ATT ATT ATT ATA-30; primer D3
(nt 107–133) 50-AAA AAC ACA AAA ACC TAA ATA TAA AAA-30
(Futscher et al, 2002). Both rounds of PCR were performed under
the same PCR conditions, with 1% of the first-round PCR product
serving as the template for the second-round PCR. PCR
amplification was performed under the following conditions: 941C
for 4 min followed by five cycles of 941C for 1 min, 561C for 2 min,
721C for 3 min, then 35 cycles of 941C for 30 s, 561C for 2 min,
721C for 1.5 min, and ending with a final extension at 721C for
6 min.
Subcloning and sequencing Amplified PCR products were
analyzed by electrophoresis on a 2% agarose gel. PCR products
were purified with a QIAquick Gel Extraction Kit (QIAGEN, Valencia,
CA). The PCR fragments were ligated to pGEM-T Easy Vectors
(Promega, Madison, WI) and transformed into DH5a-competent
cells (Toyobo, Tokyo, Japan). Ten subcloned colonies were chosen
randomly from melanoma cell lines. Plasmid DNA was purified with
a PI-200 DNA automatic isolation system (Kurabo, Osaka, Japan).
Cycle sequencing was carried out using a primer of the T7
promoter and a BigDye Terminator Cycle Sequencing FS Ready
Reaction Kit (Applied Biosystems, ABI, Foster City, California). The
product was analyzed with an ABI PRISM 3100 DNA Sequencer
(ABI).
5-Aza-20-deoxycytidine treatment Cells were seeded at a density
of 5  105 cells/10 cm plate on day 1. After 24 h, 5-aza-20-
deoxycytidine (5-Aza-dC; Sigma, St Louis, Missouri) was added to
a final concentration of 10 mM. Three days (72 h) after 5-Aza-dC
Figure 6
Microscopic features of a melanoma before (a)
and after (b) laser capture microdissection. Scale bars:
100 mm.
Table III. Correlation between methylation-speciﬁc PCR and
immunohistochemistry in 80 melanocytic tumors
Methylation-speciﬁc PCR
Immunoreactivity
Positive Negative
Methylated 0 75a
Unmethylated 5 0
apo0.01.
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treatment, the cells were harvested for western blotting and real-
time quantitative PCR (RQ-PCR).
Western blotting All melanoma cell lines were cultured to 70–
80% confluence on a 10 cm Petri dish, 1 mL of cold phosphate-
buffered saline (PBS) was added, and the cells were removed from
the dishes by scraping. The cell suspension was centrifuged at
5100 g for 1 min. After removal of the supernatant, the cell pellet
was dissolved in 1.0% NP-40 lysis buffer (50 mM HEPES (pH 7.5)/1
mM EDTA/150 mM NaCl/2.5 mM EGTA/1.0% NP-40) and rotated
at 41C for 30 min. Insoluble material was spun down (20 min,
18,000 g) and the clear supernatants were collected. The protein
concentration of the lysates was measured using a Bio-Rad DC
protein Assay Kit (Bio-Rad Laboratories, Hercules, California). Cell
lysates containing equal amounts of protein were mixed with
6  concentrated loading dye, heated for 4 min at 951C, and
subjected to SDS-PAGE on a 10% polyacrylamide gel (Bio-Rad).
The proteins were then transferred to a PVDF membrane
(Amersham Biosciences, Buckinghamshire, UK) by electroblotting.
The membrane was washed twice in 0.05% Tween-20–PBS (PBST)
for 10 min, and then blocked with 5% blocking reagent (Amersham
Biosciences) in PBST for 1 h at room temperature. The membrane
was washed twice in PBST for 10 min. The primary monoclonal
antibody against maspin (anti-human maspin antibody, clone
G167-70; Pharmingen International, San Diego, California) was
diluted 1:1000 in PBST. The membrane was incubated for 1 h at
room temperature and washed as described. The second anti-
body, anti-mouse IgG (Amersham Biosciences), was diluted
1:10,000 in blocking buffer. The membrane was incubated for 45
min at room temperature and washed. Maspin protein was
detected with ECL Plus (Amersham Biosciences).
Real-time quantitative PCR Total RNA was isolated using
TRIZOL reagent (Invitrogen, Carlsbad, California). mRNA was
reverse-transcribed with a ThermoScript RT-PCR system and
oligo(dT) (Invitrogen) to produce cDNA. In the RQ-PCR assay,
primers and a fluorogenic probe were designed with Primer
Express software (ABI): maspin F (nt 646 to 665; 50-CGA CCA
GAC CAA AAT CCT TG-30), maspin R (nt 778 to 796; 50-GAA
CGT GGC CTC CAT GTT C-30), probe (nt 745 to 772; 50-FAM-
CAA CAA GAC AGA CAC CAA ACC AGT GCA G-TAMURA-30). For
RQ-PCR, an ABI PRISM 7700 Sequence Detector (ABI) was used.
The reaction mix contained 50 ng of cDNA, 200 nmol per liter of
each primer, 5 mM probe, and 25 mL of TaqMan Universal PCR
Master Mix (ABI) in a final volume of 50 mL. The cDNA was
subjected to 50 cycles of a two-step PCR consisting of 15 s
denaturation at 951C and 1 min combined annealing/extension at
601C. Plasmids were diluted in a precise series, ranging from 5 pg
to 0.005 fg (2  106 to two copies). For normalization of each target
in the samples, the copy number of the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene was used as an internal
control. The normalized values of maspin mRNA were expressed
as the ratio of maspin copy number per 103 copy numbers of the
GAPDH gene.
Immunohistochemistry Slices (4 mM) were cut from formalin-
fixed, paraffin-embedded samples and stained with hematoxylin
and eosin. Serial sections were stained immunohistochemically. A
microwave-based antigen-retrieval method with 10 mM citrate
buffer (pH 6.0) for 15 min was performed. After deparaffinization
and antigen recovery, the sections were washed three times in PBS
for 5 min and immersed in 0.3% hydrogen peroxide in methanol for
30 min to block endogenous peroxidase activity. After three
washes with PBS for 5 min, the sections were incubated with 5%
bovine serum albumin for 10 min to block non-specific reactions.
The sections were then incubated overnight at 41C with anti-
human maspin antibody (Clone G167-70, Pharmingen) diluted
1:50. Secondary antibody and peroxidase labeling were performed
with a Simple Stain MAX-PO Kit (Nichirei, Tokyo, Japan), color-
ization was achieved with a True Blue Peroxidase Substrate Kit
(KDL, Gaithersburg, Maryland), and counterstaining was per-
formed with 0.1% Nucler Fast Red.
Laser capture microdissection and DNA extraction Ten paraf-
fin-embedded tissue sections, cut at a thickness of 5 mm, were
subjected to DNA extraction. DNAs of five maspin-positive tumors
were extracted using a laser capture microdissection (LCM) (LM-
100 PixCell LCM System, Arcturus Engineering, Mountain View,
California) as described (Bonner et al, 1997). Those of the
remaining 75 melanocytic tumors were directly extracted from
paraffin sections. Areas of interest were selected by activating the
Capsure LCM Transfer Film, which covers the region of tissue to be
acquired, and exposing tissue sections to pulses of varying
amplitude and wavelength from a short-pulse infrared laser. The
carriers of the transfer film, which are transparent caps, were then
fitted onto 1.5-mL microcentrifuge tubes. DNA was extracted from
microdissected materials of the paraffin-embedded specimens
using an EX-WAXTM DNA Extraction Kit (Intergen, Purchase,
New York).
Methylation-speciﬁc PCR (MSP) For analysis of the methylation
status of the surgical specimens, we used an MSP method. Two
sets of primers were designed to amplify specifically either the
methylated (M) (M94F: ATT TTT ATT TTA TCG AAT ATT TTA TTT TTC
Table IV. Clinical and histological characteristics of patients
Characteristics Melanoma Melanocytic nevus
Male/female 16 of 24 21 of 19
Age 5–88 y (median 64 y) 6–74 y (median 28 y)
Tumor location Tumor location
Head and neck 7 Head and neck 17
Trunk 6 Trunk 2
Extremities 9 Extremities 12
Acral 18 Acral 9
Typea Type
ALM 15 Junctional 10
LMM 7 Intradermal 17
NM 8 Compound 13
SSM 10
Tumor thickness
p1.0 mm 13
1.0–2.0 mm 7
2.0–4.0 mm 6
X4.0 mm 14
Clinical stageb
0 11
I 5
II 13
III 6
IV 5
aALM, acral lentiginous melanoma; LMM, lentigo maligna melanoma;
NM, nodular melanoma; SSM, superficial spreading melanoma.
bClinical stage was defined according to the melanoma TNM
classification (Balch et al, 2001).
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GGT/ M173R: TAC ATA CGT ACA AAC ATA CGT ACG ACA ATC
CTC TCG) or unmethylated (U) (U93F: TAT TTT TAT TTT ATT GAA
TAT TTT ATT TTT TGG T/ U173R: TAC ATA CAT ACA AAC ATA CAT
ACA ACA ATC CTC TCA) bisulfite-modified sequence, using the
MethPrimer program (http://www.methdb.de). Modified DNA was
amplified by the same method as that used in the first-round PCR
for the bisulfite genome sequencing method. The second-round
PCR was performed using 1 mL of first-round product, 25 mL of
Amplitaq Gold PCR Master Mix (ABI), and 200 nmol per liter of
each primer in a final volume of 50 mL. PCR amplification was
performed under the following conditions: 951C for 5 min followed
by 5 cycles of 951C for 30 s, 641C for 2 min, 5 cycles of 951C for 30
s, 621C for 2 min, then 30 cycles of 951C for 15 s, 601C for 1 min,
and ending with a final extension of 721C for 6 min. PCR products
were electrophoresed on 3% agarose gel.
Statistical analysis Correlations between maspin immunoreac-
tivity and clinicopathological data were compared by Mann–
Whitney U test and Kruskal–Wallis non-parametric analysis of
variance. Correlation between maspin immunoreactivity and
methylation status at the maspin promoter region was examined
by Fisher’s exact test. The level of significance was considered to
be po0.05.
DOI: 10.1111/j.0022-202X.2004.22308.x
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